Key Highlights

● Inovio soared after hours on Friday, October 30, 2026, on FDA accelerated approval.

● VOCERYQ, formerly INO-3107, treats recurrent respiratory papillomatosis in adults.

● The announcement came at 6:01 p.m. Eastern time.

● The company expects the product to be available in about 60 days.

Inovio Pharmaceuticals (NASDAQ:INO) exploded higher in after-hours trading on Friday, October 30, 2026, after the biotech company announced that the U.S. Food and Drug Administration had granted Accelerated Approval to VOCERYQ. The announcement came at 6:01 p.m. Eastern time, on the drug's PDUFA date, the deadline by which the FDA was scheduled to act on the application.

Most of the stock's move came after the regular session had closed. Market data listed Inovio among Friday's after-market movers, and a market headline described the shares as soaring after the approval. Reports differed on the exact size of the after-hours jump, and price data for the regular session was inconsistent, but the direction was unmistakable.

What VOCERYQ treats

VOCERYQ, formerly known as INO-3107, is approved for adults with recurrent respiratory papillomatosis, or RRP. The rare disease causes noncancerous growths in the respiratory tract, often requiring repeated surgeries to remove them.

In the RRP-001 study that supported the application, 7 of 26 patients needed no surgery for 12 months. Because the drug received accelerated approval, continued approval may depend on the results of a confirmatory study. Inovio said product availability is expected in about 60 days.

Dr. Jacqueline Shea, Inovio's president and CEO, said in the company's announcement that "we believe our DNA medicine platform has the potential to transform the treatment paradigm for RRP".

A milestone for the DNA medicine approach

Inovio, based in Plymouth Meeting, Pennsylvania, has spent years developing DNA medicines, which deliver genetic instructions into cells so the body can produce its own therapeutic proteins. The approval of VOCERYQ is a regulatory milestone for the company, which now turns to bringing the product to patients.

Accelerated approval is an FDA pathway that allows drugs for serious conditions with unmet needs to reach patients earlier, based on evidence that is reasonably likely to predict clinical benefit, with confirmation required later.

A rough regular session for the market

The FDA decision arrived roughly two hours after the closing bell, so the regular session did not reflect it. During regular trading hours, the broader market had a difficult day. The Nasdaq Composite dropped 747.73 points to 25,437.00, its worst day since June 5. The S&P 500 fell 140.32 points to 7,580.07, the Dow Jones Industrial Average lost 572.25 points to 51,770.31, and the Russell 2000 slid 47.37 points to 2,811.84.

Intel (NASDAQ:INTC)'s weak fourth-quarter outlook and cash-burn warning set off a chip rout that dragged the Philadelphia Semiconductor index down to 10,688.80. Amazon (NASDAQ:AMZN) reported trailing 12-month free Cash Flow of negative $42.4 billion as AI spending ballooned. Oil stayed above $100, and a reported $6.3 billion hack at crypto exchange Binance hit digital-asset stocks.

Health care was one of the market's bright spots, hitting a record high as investors rotated into defensive sectors. Regeneron (NASDAQ:REGN) was the S&P 500's top gainer after a strong quarterly report, and several large drugmakers reached 52-week highs.

What to watch

Monday's regular session will be the first full trading day after the approval, offering a clearer picture of how the market values the news. Investors will also watch for details on Inovio's commercial launch, given the company's expectation that the product will be available in about 60 days.

The confirmatory study that may be required for continued approval is another key item. More broadly, the market faces the midterm elections on Tuesday, November 3, and the October jobs report on Friday, November 6.